Additionally, our data on MGFA classifications showed that 25.9% of AChR+Titin-MG patients were classified as MGFA IIIb, while 48.3% of AChR+LRP4-MG patients were classified as MGFA IIa. The gene discussed is TTN; the disease is myasthenia gravis.